BridgeBio Pharma, Inc. Common Stock 2026 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- BridgeBio Pharma reported total revenues of $243.7 million for Q2 2026, up from $110.6 million in Q2 2025, driven primarily by a $150.9 million increase in net product revenue to $222.4 million.
- Royalty revenue increased to $15.4 million from $1.6 million year over year, mainly from sales of Bianca in the EU and Japan.
- Operating expenses rose to $335.7 million from $241.2 million, reflecting investments in sales, marketing, medical affairs, and pre-commercial supply for upcoming launches.
- Loss from operations improved by 20% year over year to $107.1 million.
- BridgeBio completed a $1 billion preferred equity financing on July 1, 2026, increasing cash and equivalents to approximately $1.7 billion.
- TruBidi (acoramidis) continued strong commercial momentum with 23% growth and expanding frontline share, supported by new kidney protective data and real world evidence.
- The overall ATTR cardiomyopathy market grew 19% quarter over quarter, a 51% increase year over year.
- All three late-stage programs (LGMD 2i, ADH1, and achondroplasia) have moved into regulatory review, with the first PDUFA date set for November 27, 2026 for LGMD 2i.
- BridgeBio's neuromuscular commercial and medical teams are hired and trained, with ongoing patient identification efforts.
- The ADH1 NDA was accepted with priority review and a May 8, 2027 target action date; the MAA has been submitted to EMA and is under review in Canada.
- Infigratinib NDA for achondroplasia was submitted with anticipated approval in mid-2027; it is the first FGFR3-targeted oral therapy with demonstrated functional benefits beyond height velocity.
- Chronic hypoparathyroidism Phase 3 trial (reclaim HP) has started screening with topline results expected in about 18 months.
- Gondola Bio's EPP program announced positive Phase 2 data and will initiate a Phase 2/3 study in Q3 2026.
- BridgeBio expects over $10 billion in risk-adjusted revenue from its pipeline, with $8 billion post-Phase 3.
- The company sees the market for acoramidis as a stabilizer-first market with constrained competitors and expects continued share growth in frontline patients.
- Cardio Transform trial of combination therapy did not meet primary endpoint, reinforcing stabilizers as first-line standard of care.
- Real world evidence shows acoramidis reduces cardiovascular events and hospitalizations compared to competitors.
- BridgeBio does not plan to compete on price but on clinical differentiation and expects parity access with competitors.
- The company expects continued growth of acoramidis even after Vyndamax goes generic in mid-2027 US.
- BridgeBio is confident in its ability to commercialize upcoming launches globally, leveraging lessons from prior launches and a strong cash position.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first five paragraphs, organized by speaker.
Good afternoon. I will be your conference operator today. All lines have been placed on mute to prevent any background noise. After the company's remarks, there will be a question and answer session. If you would like to ask a question, press star followed by the number 1 on your telephone keypad. If you would like to withdraw your question, press star 1 again. Before we begin, I would like to remind everyone that today's call may contain forward-looking statements within the meaning of the federal securities laws, including but not limited to statements about BridgeBio's future operating and financial performance, business plans and prospects, and strategy. These statements are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied in these forward-looking statements.
For a discussion of these risks and uncertainties, please refer to the disclosure in today's earnings release and BridgeBio's periodic reports and SEC filings. All statements made here are based on information available to BridgeBio as of today, and the company undertakes no obligation to update any forward-looking statements made during this call, except as required by law. With that completed, BridgeBio, you may begin your conference.
Good afternoon, everyone, and thank you for joining BridgeBio Pharma's second quarter 2026 earnings call. I am Chinmay Shukla, Senior Vice President, Strategic Finance. With me today are Neil Kumar, our CEO, who will walk through our commercial pipeline and business updates, Matt Outten, our Chief Commercial Officer, who will provide additional detail on Attruby and our launch readiness, and Tom Trimarchi, our President and CFO, who will review our financial results. During today's call, we will cover another quarter of consistent growth for Attruby, along with new data reinforcing its clinical differentiation, including the first evidence of direct kidney protection in ATTR-CM. We will then turn to the pipeline, where this quarter, all three of our late-stage programs moved from data into being with the FDA, with our first PDUFA date now set for November 27.
And we will review our financial position, including the $1 billion preferred equity financing completed on July 1, and how it supports the three launches ahead of us. Following our prepared remarks, we will open the call for questions. For the Q&A session, we will be joined by Ananth Sridhar, Christine Xu, and Justin To, who lead our programs with encaleret, BBP-418, and infigratinib respectively. With that, I will turn it over to Neil.
Thanks, Chinmay, and thanks everyone for joining today. As always, these calls are where we communicate relevant aspects of our business to investors, and so we welcome your questions and feedback. In sessions past, we've had occasion to marry comments on the portfolio with comments regarding financing and strategy. Today, however, I want to focus entirely on the portfolio itself and the progress being made across research, development, and commercial. I'm going to do so because I believe, as I hope you might appreciate at the end of my somewhat lengthy comments, that this is an important transition point for BridgeBio, one in which, if we continue executing at a high level, sets us up well for delivering substantial returns for patients and investors alike. Put more simply, it feels like we're at T equals zero in BridgeBio's next chapter.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
19 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring